Discovery and Development of ATP-Competitive mTOR Inhibitors Using Computational Approaches

被引:14
作者
Luo, Yao [1 ]
Wang, Ling [1 ]
机构
[1] South China Univ Technol, Sch Biosci & Bioengn, PreIncubator Innovat Drugs & Med, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Molecular docking; drug discovery; homology modeling; molecular dynamics; pharmacophore; machine learning; virtual screening; PI3K/MTOR DUAL INHIBITOR; FIELD ANALYSIS COMFA; RANDOMIZED PHASE-II; EVERY; WEEKS; MAMMALIAN TARGET; DRUG DESIGN; DOSE-ESCALATION; NEW-GENERATION; SIGNALING PATHWAY; KINASE INHIBITOR;
D O I
10.2174/1381612823666170710150604
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism, and angiogenesis. This protein is an attractive target for new anticancer drug development. Significant progress has been made in hit discovery, lead optimization, drug candidate development and determination of the three-dimensional (3D) structure of mTOR. Computational methods have been applied to accelerate the discovery and development of mTOR inhibitors helping to model the structure of mTOR, screen compound databases, uncover structure-activity relationship (SAR) and optimize the hits, mine the privileged fragments and design focused libraries. Besides, computational approaches were also applied to study protein-ligand interactions mechanisms and in natural product-driven drug discovery. Herein, we survey the most recent progress on the application of computational approaches to advance the discovery and development of compounds targeting mTOR. Future directions in the discovery of new mTOR inhibitors using computational methods are also discussed.
引用
收藏
页码:4321 / 4331
页数:11
相关论文
共 93 条
[1]   The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy [J].
Abraham, Robert T. ;
Gibbons, James J. .
CLINICAL CANCER RESEARCH, 2007, 13 (11) :3109-3114
[2]   Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study [J].
Asahina, Hajime ;
Nokihara, Hiroshi ;
Yamamoto, Noboru ;
Yamada, Yasuhide ;
Tamura, Yosuke ;
Honda, Kazunori ;
Seki, Yoshitaka ;
Tanabe, Yuko ;
Shimada, Hitoshi ;
Shi, Xiaojin ;
Tamura, Tomohide .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) :677-684
[3]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[4]   Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma [J].
Beck, Joseph Thaddeus ;
Ismail, Amen ;
Tolomeo, Christina .
CANCER TREATMENT REVIEWS, 2014, 40 (08) :980-989
[5]   A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma [J].
Bendell, Johanna C. ;
Kelley, Robin K. ;
Shih, Kent C. ;
Grabowsky, Jennifer A. ;
Bergsland, Emily ;
Jones, Suzanne ;
Martin, Thomas ;
Infante, Jeffrey R. ;
Mischel, Paul S. ;
Matsutani, Tomoo ;
Xu, Shuichan ;
Wong, Lilly ;
Liu, Yong ;
Wu, Xiaoling ;
Mortensen, Deborah S. ;
Chopra, Rajesh ;
Hege, Kristen ;
Munster, Pamela N. .
CANCER, 2015, 121 (19) :3481-3490
[6]   Rapamycin passes the torch: a new generation of mTOR inhibitors [J].
Benjamin, Don ;
Colombi, Marco ;
Moroni, Christoph ;
Hall, Michael N. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) :868-880
[7]   Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin [J].
Bhagwat, Shripad V. ;
Gokhale, Prafulla C. ;
Crew, Andrew P. ;
Cooke, Andy ;
Yao, Yan ;
Mantis, Christine ;
Kahler, Jennifer ;
Workman, Jennifer ;
Bittner, Mark ;
Dudkin, Lorina ;
Epstein, David M. ;
Gibson, Neil W. ;
Wild, Robert ;
Arnold, Lee D. ;
Houghton, Peter J. ;
Pachter, Jonathan A. .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) :1394-1406
[8]  
Burris H, 2015, CANCER RES, P75
[9]   A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma [J].
Carlo, Maria I. ;
Molina, Ana M. ;
Lakhman, Yulia ;
Patil, Sujata ;
Woo, Kaitlin ;
DeLuca, John ;
Lee, Chung-Han ;
Hsieh, James J. ;
Feldman, Darren R. ;
Motzer, Robert J. ;
Voss, Amartin H. .
ONCOLOGIST, 2016, 21 (07) :787-788
[10]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404